BR-101
- Generic Name
- BR-101
A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06001580
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath